357 related articles for article (PubMed ID: 26491291)
1. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma.
Yao Y; Wang T; Liu Y; Zhang N
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1374-1383. PubMed ID: 30977418
[TBL] [Abstract][Full Text] [Related]
3. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
Zhao M; Lee SH; Song JG; Kim HY; Han HK
Int J Pharm; 2018 Jun; 544(1):14-20. PubMed ID: 29655795
[TBL] [Abstract][Full Text] [Related]
5. A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery.
Li P; Liu D; Miao L; Liu C; Sun X; Liu Y; Zhang N
Int J Nanomedicine; 2012; 7():925-39. PubMed ID: 22393290
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
7. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
[TBL] [Abstract][Full Text] [Related]
8. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Xiao Y; Liu Y; Yang S; Zhang B; Wang T; Jiang D; Zhang J; Yu D; Zhang N
Colloids Surf B Biointerfaces; 2016 May; 141():83-92. PubMed ID: 26844644
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
Wang T; Zhang J; Hou T; Yin X; Zhang N
Nanoscale; 2019 Aug; 11(29):13934-13946. PubMed ID: 31305839
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
14. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.
Song C; Zhang J; Wen R; Li Q; Zhou J; Xiaoli Liu ; Wu Z; Lv Y; Wu R
Mater Today Bio; 2022 Dec; 16():100350. PubMed ID: 35856043
[TBL] [Abstract][Full Text] [Related]
15. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
Elzeny H; Zhang F; Ali EN; Fathi HA; Zhang S; Li R; El-Mokhtar MA; Hamad MA; Wooley KL; Elsabahy M
Drug Des Devel Ther; 2017; 11():483-496. PubMed ID: 28260861
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization and antitumor evaluation of CMCS-DTX conjugates as novel delivery platform for docetaxel.
Liu F; Feng L; Zhang L; Zhang X; Zhang N
Int J Pharm; 2013 Jul; 451(1-2):41-9. PubMed ID: 23608199
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential of a simplified co-delivery system with oligodeoxynucleotides as a drug carrier for enhanced antitumor effect.
Liu C; Liu T; Liu Y; Zhang N
Int J Nanomedicine; 2018; 13():2435-2445. PubMed ID: 29719392
[TBL] [Abstract][Full Text] [Related]
18. Inducing sustained release and improving oral bioavailability of curcumin via chitosan derivatives-coated liposomes.
Tian MP; Song RX; Wang T; Sun MJ; Liu Y; Chen XG
Int J Biol Macromol; 2018 Dec; 120(Pt A):702-710. PubMed ID: 30170061
[TBL] [Abstract][Full Text] [Related]
19. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Wen Z; Feng Y; Hu Y; Lian L; Huang H; Guo L; Chen S; Yang Q; Zhang M; Wan L; Xu K; Degejirifu ; Yan X
Aging (Albany NY); 2021 Jan; 13(2):1872-1882. PubMed ID: 33440348
[TBL] [Abstract][Full Text] [Related]
20. Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.
Zhang R; Wang SB; Chen AZ; Chen WG; Liu YG; Wu WG; Kang YQ; Ye SF
J Biomater Appl; 2015 Sep; 30(3):351-60. PubMed ID: 25838353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
